【摘要】 目的探讨Ki-67和乙醛脱氢酶1(ALDH1)联合检测对判断三阴性乳腺癌(TNBC)新辅助化疗(NACT)效果的价值。方法回顾性分析完成NACT的52例TNBC患者资料,分析化疗前Ki-67和ALDH1的不同表达情况与NACT后病理完全缓解(pCR)之间的相关性。结果 52例中,20例(38.5%)NACT后获得pCR。Ki-67阳性表达组pCR率65.2%(15/23),高于Ki-67阴性表达组的17.2%(5/29)(P<0.05)。ALDH1阳性表达组pCR率15.6%(5/32),低于ALDH1阴性表达组的75.0%(15/20)(P<0.01)。Ki-67阳性且ALDH1阴性表达组pCR率为93.8%(15/16),高于Ki-67阳性且ALDH1阳性表达组或Ki-67阴性且ALDH1阳性表达组(P<0.05)。结论 TNBC组织中Ki-67阳性且ALDH1阴性表达患者对NACT效果好,Ki-67阳性且ALDH1阴性可作为预测TNBC的NACT疗效的分子标记物。更多还原

【Abstract】 Objective To evaluate the role of combined detection of Ki-67 and aldehyde dehydrogenase 1(ALDH1) in predicting the effectiveness of neoadjuvant chemotherapy(NACT) in the patients with triple-negative breast cancer(TNBC).Methods Data of 52 TNBC patients treated with NACT were retrospectively reviewed.The relationship between the different expressions of Ki-67 and ALDH1 and the pathological complete remission(pCR) rate was analyzed.Results The pCR rate in 52 cases was 38.5%(20/52).The pCR rate of the patients with positive expression of Ki-67 was 65.2%(15/23),which was significantly higher than 17.2%(5/29) of those with Ki-67 negative-expression(P<0.05).The pCR rate of the patients with positive expression of ALDH1 was 15.6%(5/32),which was significantly lower than 75.0%(15/20) of those with negative expression of ALDH1(P<0.01).The pCR rate in the patients with positive expression of Ki-67 and negative expression of ALDH1 was 93.8%(15/16),which was significantly higher than that of the patients with positive expression of Ki-67 and positive expression of ALDH1 or the patients with negative expression of Ki-67 and positive expression of ALDH1.Conclusion The pCR rate in the patients with both positive expression of Ki-67 and negative expression of ALDH1 is high.Positive expression of Ki-67 and negative expression of ALDH1 can well predict the effectiveness of NACT in TNBC patients.更多还原